GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CRISPR Therapeutics AG (NAS:CRSP) » Definitions » Asset Turnover

CRISPR Therapeutics AG (CRISPR Therapeutics AG) Asset Turnover : 0.09 (As of Dec. 2023)


View and export this data going back to 2016. Start your Free Trial

What is CRISPR Therapeutics AG Asset Turnover?

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. CRISPR Therapeutics AG's Revenue for the three months ended in Dec. 2023 was $200.0 Mil. CRISPR Therapeutics AG's Total Assets for the quarter that ended in Dec. 2023 was $2,158.2 Mil. Therefore, CRISPR Therapeutics AG's Asset Turnover for the quarter that ended in Dec. 2023 was 0.09.

Asset Turnover is linked to ROE % through Du Pont Formula. CRISPR Therapeutics AG's annualized ROE % for the quarter that ended in Dec. 2023 was 19.80%. It is also linked to ROA % through Du Pont Formula. CRISPR Therapeutics AG's annualized ROA % for the quarter that ended in Dec. 2023 was 16.56%.


CRISPR Therapeutics AG Asset Turnover Historical Data

The historical data trend for CRISPR Therapeutics AG's Asset Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CRISPR Therapeutics AG Asset Turnover Chart

CRISPR Therapeutics AG Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Asset Turnover
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.37 - 0.40 - 0.17

CRISPR Therapeutics AG Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Asset Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 0.05 0.03 - 0.09

Competitive Comparison of CRISPR Therapeutics AG's Asset Turnover

For the Biotechnology subindustry, CRISPR Therapeutics AG's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CRISPR Therapeutics AG's Asset Turnover Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CRISPR Therapeutics AG's Asset Turnover distribution charts can be found below:

* The bar in red indicates where CRISPR Therapeutics AG's Asset Turnover falls into.



CRISPR Therapeutics AG Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

CRISPR Therapeutics AG's Asset Turnover for the fiscal year that ended in Dec. 2023 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (A: Dec. 2023 )/( (Total Assets (A: Dec. 2022 )+Total Assets (A: Dec. 2023 ))/ count )
=370/( (2243.057+2229.571)/ 2 )
=370/2236.314
=0.17

CRISPR Therapeutics AG's Asset Turnover for the quarter that ended in Dec. 2023 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (Q: Dec. 2023 )/( (Total Assets (Q: Sep. 2023 )+Total Assets (Q: Dec. 2023 ))/ count )
=200/( (2086.83+2229.571)/ 2 )
=200/2158.2005
=0.09

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.


CRISPR Therapeutics AG  (NAS:CRSP) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

CRISPR Therapeutics AG's annulized ROE % for the quarter that ended in Dec. 2023 is

ROE %**(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=357.388/1805.2985
=(Net Income / Revenue)*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(357.388 / 800)*(800 / 2158.2005)*(2158.2005/ 1805.2985)
=Net Margin %*Asset Turnover*Equity Multiplier
=44.67 %*0.3707*1.1955
=ROA %*Equity Multiplier
=16.56 %*1.1955
=19.80 %

Note: The Net Income data used here is four times the quarterly (Dec. 2023) net income data. The Revenue data used here is four times the quarterly (Dec. 2023) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

CRISPR Therapeutics AG's annulized ROA % for the quarter that ended in Dec. 2023 is

ROA %(Q: Dec. 2023 )
=Net Income/Total Assets
=357.388/2158.2005
=(Net Income / Revenue)*(Revenue / Total Assets)
=(357.388 / 800)*(800 / 2158.2005)
=Net Margin %*Asset Turnover
=44.67 %*0.3707
=16.56 %

Note: The Net Income data used here is four times the quarterly (Dec. 2023) net income data. The Revenue data used here is four times the quarterly (Dec. 2023) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.


CRISPR Therapeutics AG Asset Turnover Related Terms

Thank you for viewing the detailed overview of CRISPR Therapeutics AG's Asset Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.


CRISPR Therapeutics AG (CRISPR Therapeutics AG) Business Description

Traded in Other Exchanges
Address
Baarerstrasse 14, Zug, CHE, CH-6300
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, exa-cel, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Executives
Samarth Kulkarni officer: Chief Business Officer C/O CRISPR THERAPEUTICS AG, 200 SIDNEY STREET, CAMBRIDGE MA 02139
Raju Prasad officer: Chief Financial Officer CRISPR THERAPEUTICS, INC., 105 W FIRST STREET, BOSTON MA 02127
Phuong Khanh Morrow officer: Chief Medical Officer C/O CRISPR THERAPEUTICS, 610 MAIN STREET, CAMBRIDGE MA 02139
Maria Fardis director C/O PARMACYCLICS, INC., 995 EAST ARQUES AVENUE, SUNNYVALE CA 94085
Brendan Smith officer: Chief Financial Officer 29 HARTWELL AVENUE, LEXINGTON MA 02421
Michael John Tomsicek officer: Chief Financial Officer 28 OVERLOOK DRIVE, BEDFORD MA 01730
Bolzon Bradley J Phd director ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104
Rodger Novak director, officer: Chief Executive Officer C/O CRISPR THERAPEUTICS AG, 200 SIDNEY STREET, CAMBRIDGE MA 02139
Harold Edward Fleming director C/O CRISPR THERAPEUTICS AG, 610 MAIN STREET, CAMBRIDGE MA 02139
Lawrence Otto Klein officer: Chief Business Officer C/O CRISPR THERAPEUTICS AG, 610 MAIN STREET 7TH FLOOR, CAMBRIDGE MA 02139
James R. Kasinger officer: General Counsel and Secretary C/O CRISPR THERAPEUTICS, INC., 610 MAIN STREET, CAMBRIDGE MA 02139
Tony W Ho officer: See Remarks CRISPR THERAPEUTICS AG, 610 MAIN STREET, CAMBRIDGE MA 02139
Douglas A Treco director 87 CAMBRIDGEPARK DRIVE, C/O RA PHARMACEUTICALS, INC., CAMBRIDGE MA 02140
Pablo J Cagnoni director ONYX PHARMACEUTICALS, INC., 249 E. GRAND AVE., SOUTH SAN FRANCISCO CA 94080
Katherine A High director 3737 MARKET STREET, SUITE 1300, PHILADELPHIA PA 19104